Zogenix shares down 23% after FDA refuses to review company’s marketing application for seizure drug

Shares of Zogenix, Inc. plunged 23% Tuesday after the company disclosed Monday evening that the Food and Drug Administration had refused to review the marketing application for a treatment of seizures associated with a rare form of childhood epilepsy.